Trigeminal Neuralgia: Treatment in Malaysia

Trigeminal neuralgia has been called the “suicide disease” — not by clinicians as clinical terminology, but by the patients who have lived with it. The pain is unlike almost anything else in medicine: sudden, electric, triggered by the lightest touch, and utterly incapacitating.

I treat trigeminal neuralgia from both ends of the spectrum — from medication optimisation through to microvascular decompression surgery — and I believe every patient deserves a clear explanation of all available options, not just the ones their referring doctor happens to know about.

What Is Trigeminal Neuralgia?

Trigeminal neuralgia (TN) is a chronic pain condition affecting the trigeminal nerve (cranial nerve V) — the nerve responsible for sensation across the face. It is characterised by sudden, severe, electric shock-like facial pain that is typically:

• Unilateral (one side of the face)
• Brief (seconds to 2 minutes per episode)
• Triggered by light touch — brushing teeth, eating, speaking, cold wind, shaving
• Lancinating — stabbing, burning, electric in quality
• In the V2 or V3 distribution — cheek, jaw, teeth, gums, lips (less commonly V1 — forehead, eye)

The pain-free intervals between attacks can last weeks to months, leading to misdiagnosis as dental pain, sinus disease, or TMJ disorder. Delayed diagnosis of 3–7 years is unfortunately common.

Causes

Classical TN (most common): A blood vessel — usually the superior cerebellar artery — pressing on the trigeminal nerve root at the brainstem. The pulsating contact causes demyelination and aberrant electrical firing.

Secondary TN: Caused by an identifiable structural lesion — multiple sclerosis plaque, brain tumour (acoustic neuroma, meningioma), or arteriovenous malformation pressing on the nerve. MRI is essential to exclude these causes.

Idiopathic TN: No identifiable cause on imaging. Managed medically and with percutaneous procedures.

Diagnosis

MRI Brain with fine-cut posterior fossa sequences (FIESTA/CISS protocol) is the investigation of choice — it can visualise the neurovascular contact at the root entry zone and exclude secondary causes.

Neurophysiology (trigeminal reflexes) may provide additional evidence in uncertain cases.

A correct anatomical diagnosis guides treatment selection: patients with clear neurovascular contact on MRI are the best candidates for microvascular decompression.

Treatment Options

1. Medication (First-Line)

Carbamazepine (Tegretol) — the only FDA-approved medication for TN, and remains first-line. Effective in 70–80% of patients initially. Dose-dependent side effects (drowsiness, unsteadiness) limit tolerability at higher doses.

Oxcarbazepine — better tolerated than carbamazepine, similar efficacy.

Baclofen, lamotrigine, gabapentin — second-line agents, often used in combination.

The challenge: over time, 50% of patients develop drug resistance or intolerable side effects. When this happens, procedural options should be discussed without delay.

2. Percutaneous Procedures

Performed under light sedation, through a needle passed through the cheek into the trigeminal ganglion at the skull base (foramen ovale).

Radiofrequency Thermocoagulation (RFT) Controlled heat lesioning of the trigeminal ganglion. Immediate pain relief in >90% of patients. Risk of facial numbness (usually partial, acceptable trade-off). Recurrence rate 20–30% at 3–5 years — procedure can be repeated.

Glycerol Rhizolysis Chemical neurolysis of the trigeminal ganglion using glycerol. Similar efficacy to RFT, lower risk of anaesthesia dolorosa (a rare but distressing burning numbness complication).

Balloon Compression A small balloon is inflated in Meckel’s cave to compress the trigeminal ganglion. Effective, particularly for V1 distribution pain.

I offer percutaneous procedures as outpatient or day surgery. Recovery is typically same-day.

3. Microvascular Decompression (MVD)

The only treatment that addresses the underlying cause — moving the offending blood vessel away from the nerve root and placing a small Teflon sponge between them.

MVD is the most durable treatment for TN: 80–90% long-term pain freedom at 10 years in appropriately selected patients. It preserves facial sensation — unlike percutaneous procedures which work by damaging the nerve.

Who is the best MVD candidate?

• Younger patients (<70 years) without major comorbidities
• Clear neurovascular contact on MRI
• Typical TN (V2/V3 distribution, triggered by touch)
• Failed or intolerant of medications

MVD requires a posterior fossa craniotomy — a real operation with real risks (1–2% serious complication rate). The trade-off is the best long-term outcome of any available treatment.

I perform MVD regularly at KPJ Tawakkal Specialist Hospital. Hospital stay is typically 3–4 days.

4. Stereotactic Radiosurgery (Gamma Knife)

Non-invasive, outpatient procedure delivering a precisely focused radiation dose to the trigeminal nerve root. No incision. Efficacy is slightly lower than MVD, and pain relief may be delayed by weeks. Best suited for patients who are not surgical candidates.

Making the Decision

There is no single right answer for every TN patient. The decision between percutaneous procedure, MVD, and radiosurgery depends on age, health, MRI findings, distribution of pain, and personal preference.

What I commit to: I will explain all the options clearly, give you my honest recommendation, and respect your choice.

WhatsApp the clinic: +6011 3723 5061 Book online: KPJ Tawakkal Appointment Portal Call the clinic: +603-4026 7777 ext 5099

Educational purposes only. All treatment decisions require direct clinical consultation.